Novartis drug Afinitor significantly extended time without disease progression ... MarketWatch (press release) Basel, May 17, 2013 - Results of a pivotal Phase III trial in women with HER2 positive (HER2+) advanced breast cancer showed that Afinitor� (everolimus) tablets in combination with trastuzumab (Herceptin�*) and vinorelbine significantly extended ... |
